相关实验视频

Updated: Jun 7, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

用小格式免疫细胞因子准PD-1+T细胞可以增强IL-12抗瘤活性

Noelia Silva-Pilipich¹, Uxue Beloki², Patricia Apaolaza²

¹DNA and RNA Medicine Division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA) and CCUN, 31008 Pamplona, Spain; Nanogrow Biotech, Montevideo 11500, Uruguay.

Molecular therapy : the journal of the American Society of Gene Therapy

|November 20, 2024

概括

研究人员开发了新型免疫细胞因子 (ICKs),将互白素-12 (IL-12) 与向PD-1或PD-L1.1的纳米体结合起来. 用抗PD-1 ICK 准T细胞比瘤定策略更有效地增强了抗瘤活性.

科学领域:

免疫学免疫学免疫学
癌症治疗方法癌症治疗方法
生物技术是生物技术.

背景情况:

免疫刺激性细胞因子和免疫检查点抑制剂是有前途的癌症疗法.
它们的临床使用往往受到毒性和效率降低的限制.

研究的目的:

通过将介质素-12 (IL-12) 与向PD-1和PD-L1.1的纳米体 (Nbs) 融合,开发小格式免疫细胞因子 (ICK).
评估这些ICK在癌症治疗中的体外和体内疗效.

主要方法:

结合IL-12和抗PD-1或抗PD-L1纳米体的工程ICK.
在体外评估免疫细胞结合和T细胞活性.
在小鼠模型中通过RNA载体或重组蛋白质的内输送来评估抗瘤疗效.

主要成果:

针对PD-1和PD-L1的ICK在体外增强了IL-12结合和T细胞活性.
对抗PD-1 ICKs的内输送显著提高了IL-12介导的抗瘤疗效.
通过抗PD-1向内T细胞比PD-L1瘤定更有效.

结论:

针对瘤微环境中的特定免疫细胞对于有效的IL-12疗法至关重要.
抗PD-1免疫细胞因子显示出增强癌症治疗的潜力.
发达的人类ICKs在人类免疫细胞中活跃,这表明临床翻译潜力.

关键词:

阿尔法病毒阿尔法病毒在PD-1/PD-L1中.检查站封锁检查站封锁免疫细胞因子的免疫细胞因子.介质蛋白-12 介质蛋白-12 是一种纳米体是一个纳米体.自强化RNA的自强化RNA.

更多相关视频

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...